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The report on the Ebola virus disease which appeared in a
recent issue of this publication was very interesting.1 Tseng
and Chan noted that “there is no standard treatment for EVD”
and also mentioned that “to promptly identify patients and
prevent further spread, physicians should be aware of travel or
contact history for patients with constitutional symptoms.”1
These two points should be further discussed. Certainly, as
an emerging disease, knowledge about the treatment of the
Ebola virus disease is limited.2 However, within the past
several months, there are many newly published guidelines
specifically addressing the new Ebola virus disease. Several
good examples are those published in MMWR Morb Mortal
Wkly Rep and BMJ.3,4 Such guidelines can be extremely
useful, and should be further adapted to individual settings.
Focusing on early diagnosis, it is acceptable as a good tool for
disease control.2 However, there are many problems regarding
early diagnosis. First, asymptomatic infection is possible and
this cannot be easily detected.5,6 Second, the problem of false
negative readings as a part of case diagnosis has been repor-
ted.7 This problem can also be seen in the modern PCR test.8
Alternatively, false positives in diagnosis have also been
observed.9 Adding to the basic limited availability of the test,
the problem of false diagnosis must be kept in mind when one
deals with the problem of the newly-emerging Ebola virus
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